Do you offer the addition of necitumumab to first-line chemotherapy for patients with advanced/metastatic squamous cell NSCLC?

There are multiple competing therapeutic strategies for patients with advanced stage squamous cell carcinoma Recent data does demonstrate that the addition of necitumumab to cisplatin/gemcitabine improves survival by six weeks when compared to cisplatin/gemcitabine alone (SQUIRE study). The pros of ...